144 results

Choose a module

70 medications

Now Available

ALPHAAvailable NowAntibiotic

gepotidacin

Blujepa

Uncomplicated urinary tract infections and uncomplicated urogenital gonorrhea

EAGLE-2/3 uUTIEAGLE-1 gonorrhea
Approval: March 25, 2025Sponsor: GSK

Gepotidacin (Blujepa) Summary

FDA approved gepotidacin (Blujepa) in March 2025 for uncomplicated urinary tract infection in female patients aged 12 years and older who weigh at least 40 kg. This oral antibacterial inhibits bacterial DNA gyrase and topoisomerase IV through a binding site distinct from established antibiotic classes.

Approval was supported by the randomized EAGLE-2 and EAGLE-3 trials. Gepotidacin was noninferior to nitrofurantoin on the combined clinical and microbiological response at test of cure: 51.8% versus 47.0% in EAGLE-2 and 58.9% versus 44.0% in EAGLE-3.

Latest label expansion. In December 2025, FDA added uncomplicated urogenital gonorrhea for patients aged 12 years and older who weigh at least 45 kg and have limited or no alternative treatment options. The label notes limited clinical safety data for this use.

Upcoming Modules

New Modules Released Weekly

ALPHAAntibioticAvailable NowAnti-infective

gepotidacin

Blujepa

Uncomplicated urinary tract infections and uncomplicated urogenital gonorrhea

Approval: Mar 25, 2025Sponsor: GSK
ALPHAPCSK9 inhibitorCardiology

lerodalcibep-liga

Lerochol

Hypercholesterolemia, including HeFH

Approval: Dec 12, 2025Sponsor: LIB Therapeutics
ALPHAIL-23 receptor antagonistDermatology

icotrokinra

Icotyde

Plaque psoriasis in patients age 12 years and older

Approval: Mar 17, 2026Sponsor: J&J/Janssen
ALPHAGLP-1 receptor agonistMetabolic

orforglipron

Foundayo

Chronic weight management

Approval: Apr 1, 2026Sponsor: Eli Lilly
ALPHAAnti-infective

ensitrelvir

Xocova

COVID-19 post-exposure prophylaxis

Approval: May 29, 2026Sponsor: Shionogi
ALPHAAnti-infective

clesrovimab-cfor

Enflonsia

Prevention of RSV lower respiratory tract disease in neonates and infants entering their first RSV season

Approval: Jun 9, 2025Sponsor: Merck
ALPHAAnti-infective

doravirine and islatravir

Idvynso

Replacement regimen for virologically suppressed adults with HIV-1

Approval: Apr 20, 2026Sponsor: Merck Sharp & Dohme
ALPHAPCSK9 inhibitorCardiology

enlicitide

Lipfendra

LDL-C reduction in adults with hypercholesterolemia, including HeFH

Approval: Jul 2026Sponsor: Merck
ALPHANaV1.8 inhibitorAcute painNaV1.8

suzetrigine

Journavx

Moderate-to-severe acute pain

Approval: Jan 30, 2025Sponsor: Vertex

Available Resources

70 drugs

Featured
suzetrigineJournavxAcute painJan 30, 2025

Moderate-to-severe acute pain

NaV1.8 inhibitorNeurology & psychiatryALPHANaV1.8
Brand
Journavx
Therapy
Acute pain
Type
NaV1.8 inhibitor
Approval
Jan 30, 2025
Sponsor
Vertex
gepotidacinBlujepaAnti-infectiveMar 25, 2025

Uncomplicated urinary tract infections and uncomplicated urogenital gonorrhea

AntibioticInfectious diseaseALPHAAvailable Now
Brand
Blujepa
Therapy
Anti-infective
Type
Antibiotic
Approval
Mar 25, 2025
Sponsor
GSK
lerodalcibep-ligaLerocholCardiologyDec 12, 2025

Hypercholesterolemia, including HeFH

PCSK9 inhibitorCardiology & nephrologyALPHA
Brand
Lerochol
Therapy
Cardiology
Type
PCSK9 inhibitor
Approval
Dec 12, 2025
Sponsor
LIB Therapeutics
icotrokinraIcotydeDermatologyMar 17, 2026

Plaque psoriasis in patients age 12 years and older

IL-23 receptor antagonistDermatology & immunologyALPHA
Brand
Icotyde
Therapy
Dermatology
Type
IL-23 receptor antagonist
Approval
Mar 17, 2026
Sponsor
J&J/Janssen
orforglipronFoundayoMetabolicApr 1, 2026

Chronic weight management

GLP-1 receptor agonistEndocrinologyALPHA
Brand
Foundayo
Therapy
Metabolic
Type
GLP-1 receptor agonist
Approval
Apr 1, 2026
Sponsor
Eli Lilly
ensitrelvirXocovaAnti-infectiveMay 29, 2026

COVID-19 post-exposure prophylaxis

Anti-infectiveOther specialty careALPHA
Brand
Xocova
Therapy
Anti-infective
Type
Anti-infective
Approval
May 29, 2026
Sponsor
Shionogi
clesrovimab-cforEnflonsiaAnti-infectiveJun 9, 2025

Prevention of RSV lower respiratory tract disease in neonates and infants entering their first RSV season

Anti-infectiveOther specialty careALPHA
Brand
Enflonsia
Therapy
Anti-infective
Type
Anti-infective
Approval
Jun 9, 2025
Sponsor
Merck
doravirine and islatravirIdvynsoAnti-infectiveApr 20, 2026

Replacement regimen for virologically suppressed adults with HIV-1

Anti-infectiveInfectious diseaseALPHA
Brand
Idvynso
Therapy
Anti-infective
Type
Anti-infective
Approval
Apr 20, 2026
Sponsor
Merck Sharp & Dohme
enlicitideLipfendraCardiologyJul 2026

LDL-C reduction in adults with hypercholesterolemia, including HeFH

PCSK9 inhibitorCardiology & nephrologyALPHA
Brand
Lipfendra
Therapy
Cardiology
Type
PCSK9 inhibitor
Approval
Jul 2026
Sponsor
Merck
esketamineSpravatoNeuropsychiatry / PainMar 5, 2019

To treat treatment-resistant depression

NMDA receptor antagonistNeurology & psychiatry
Brand
Spravato
Therapy
Neuropsychiatry / Pain
Type
NMDA receptor antagonist
Modality
Small molecule
Approval
Mar 5, 2019
Sponsor
Janssen Pharmaceuticals

1–10 of 70

Entries per page